Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO-Reference-Cited by-同舟云学术

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Published:2017-12 Issue:6 Volume:119 Page:524-532.e2
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Chipps Bradley E.,Zeiger Robert S.,Luskin Allan T.,Busse William W.,Trzaskoma Benjamin L.,Antonova Evgeniya N.,Pazwash Hooman,Limb Susan L.,Solari Paul G.,Griffin Noelle M.,Casale Thomas B.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology

Reference73 articles.

1. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study;Bjermer;Chest,2016

2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial;Bleecker;Lancet,2016

3. Benralizumab, an anti–interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study;Castro;Lancet Respir Med,2014

4. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials;Castro;Lancet Respir Med,2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study;Respiratory Medicine;2024-05

2. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL;World Allergy Organization Journal;2023-06

3. Definitions of non-response and response to biological therapy for severe asthma: a systematic review;ERJ Open Research;2023-01-26

4. Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility;The Journal of Allergy and Clinical Immunology: In Practice;2022-08

5. Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma;Journal of Personalized Medicine;2022-01-26